Yinuoqing® is the commercial brand name of Efsubaglutide alfa Injection, a long‑acting GLP‑1 receptor agonist developed by Innogen. It activates GLP‑1 receptors to slow gastric emptying, suppress appetite and regulate glucose metabolism.
Main Indications
For the treatment of type 2 diabetes mellitus in adult patients to improve glycemic control, together with diet and exercise.
Clinical Research
Phase III clinical trials demonstrated that once-weekly efsubaglutide alfa significantly reduced HbA1c and body weight. It showed durable glycemic-lowering efficacy with a gastrointestinal adverse event profile similar to other GLP‑1 agonists.
Common Side Effects
Nausea, vomiting, diarrhea, constipation;
Other common reactions: injection site reactions, decreased appetite. Rare serious adverse events include pancreatitis, thyroid C-cell tumor risk and severe hypersensitivity.
Approval Status in China
Original drug Yinuoqing® (Efsubaglutide alfa Injection) was officially approved for marketing in China in 2025, with the specification of 1mg (0.5ml) per pen, 2 pre-filled auto-injectors per box. It is currently a prescription drug.
Buy Yinuoqing (Efsubaglutide alfa Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
